Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses
about
Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogensModeling Influenza Virus Infection: A Roadmap for Influenza ResearchDeveloping Universal Influenza Vaccines: Hitting the Nail, Not Just on the HeadAdvances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccinesNonreplicating influenza A virus vaccines confer broad protection against lethal challengeAdenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenzaEvolution of H3N2 influenza virus in a guinea pig modelIntranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in miceMVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 virusesMucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model.Advances in influenza vaccination.Adenoviral vectors as novel vaccines for influenza.Prior population immunity reduces the expected impact of CTL-inducing vaccines for pandemic influenza control.Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.Single-Dose CpG Immunization Protects Against a Heterosubtypic Challenge and Generates Antigen-Specific Memory T Cells.Cross-protective immunity to influenza A viruses.Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferretsImmunogenicity and Cross Protection in Mice Afforded by Pandemic H1N1 Live Attenuated Influenza Vaccine Containing Wild-Type Nucleoprotein.Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice.Mimotopes selected with neutralizing antibodies against multiple subtypes of influenza A.Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunityInfluenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence.Memory CD4 T cell-mediated immunity against influenza A virus: more than a little helpful.Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease.Mucosal immunization with integrase-defective lentiviral vectors protects against influenza virus challenge in miceSurveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 PandemicHeterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administrationIntranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge.Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice.Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coliCooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity.M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A.Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus.Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection.Influenza vaccines: challenges and solutions.Intranasal administration of adeno-associated virus type 12 (AAV12) leads to transduction of the nasal epithelia and can initiate transgene-specific immune responseProtective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.Age Dependence of Immunity Induced by a Candidate Universal Influenza Vaccine in MiceLarge intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection
P2860
Q26750912-9A3A1B79-78CD-4ACE-A878-793FE2B5457FQ26782421-4278A4E4-8F36-4C9C-AEC1-EF7129330CA2Q26783897-BEC5F900-DF91-4799-B5B6-D15C3952DD50Q27013568-BB1E08DE-127F-4C6F-9929-EEEFEDEAAD33Q28392109-638C5457-7941-409C-9F2F-C3E808188F7FQ28479491-DA5F69C6-9EAA-4694-B01B-7C272465A2AFQ28742283-647BCD7E-0A98-4099-AC10-2A052B801334Q28744391-6F6B8B6F-0EA4-417C-9A17-F7AD1E2D2F0FQ30358935-67ECB76E-7133-4E5B-BA69-E7D9E7C38757Q30360144-1FD1AD72-4B0A-4920-8E99-BF05E536AB55Q30364315-8E71F273-6C08-4F7A-94FE-102ECB6B3570Q30370445-E9F3F07A-F65E-4D97-9F5A-B02182C8554CQ30373077-43372F88-D162-4A1D-9630-5947A16843ABQ30373993-DC6E3648-6162-4A51-BE0C-8C85AB399C83Q30376518-98A3C2CF-DAF0-48A4-8A8C-298D3A6BA249Q30396399-94699426-FB1E-499A-AB1F-FBEE3F4032C8Q30398516-15B85887-AEC9-4B81-B1CB-EE91668755C0Q30398731-15336BC4-B1C3-4B3A-9908-AAA707D36CA0Q30405211-00EA0C1A-BA17-4D4C-94E7-174CAF10D42DQ30410691-A375E82F-FD83-4D66-AAA1-A323130FC965Q30421682-67F6BA8A-9BB7-4B47-92A2-2BA17BBC1795Q30429719-50841B34-6D9C-4864-B355-9EB9F1A2E218Q30431078-BCC711DF-D84C-4CCF-8603-B33BB16F2311Q30431135-A36B3691-C4F3-4839-AB4C-1B00ECEF3DB9Q33604567-198CB973-55EB-49E4-873A-336BD9225C2BQ33904286-7B77FFCD-971C-4176-B5D1-F7B68DF4788AQ33958402-91A74EDD-650B-46B4-8979-20044FEA9CF7Q34070683-1DF92E6F-58EB-4F9F-9920-6068D398D761Q34105207-FD39AB38-13CE-4305-BADE-B3F5FD53A258Q34533990-C2E24BBC-40BD-4947-BFAC-DBB367DCC65FQ34629133-3E2F613A-1B7C-41FD-9C5D-33EAAF81E09EQ34634610-F5DC2E12-8B2F-46B6-AE38-A718C70BAD59Q34638916-2AB879FB-8265-4135-A700-574350AAAECFQ34947144-93ED70BD-9AAB-4567-A428-CE2AB2EE8630Q35005641-B15C026D-156F-4B88-9695-2745FFCE19DEQ35184572-E52C0379-73B6-445C-A20B-1D806743B8CDQ35568518-674BA843-EAD3-410A-BAEE-C927D2D78BFEQ35656657-21B6CE26-D2AF-49A3-9C75-C1378234DE26Q35982805-B6A7D706-5A10-4EA2-849D-A22A8079C927Q36331205-CB12F6E2-B59B-4A35-813A-A286C0ABB338
P2860
Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Single-dose mucosal immunizati ...... nt H5N1, H3N2 and H1N1 viruses
@ast
Single-dose mucosal immunizati ...... nt H5N1, H3N2 and H1N1 viruses
@en
Single-dose mucosal immunizati ...... nt H5N1, H3N2 and H1N1 viruses
@nl
type
label
Single-dose mucosal immunizati ...... nt H5N1, H3N2 and H1N1 viruses
@ast
Single-dose mucosal immunizati ...... nt H5N1, H3N2 and H1N1 viruses
@en
Single-dose mucosal immunizati ...... nt H5N1, H3N2 and H1N1 viruses
@nl
prefLabel
Single-dose mucosal immunizati ...... nt H5N1, H3N2 and H1N1 viruses
@ast
Single-dose mucosal immunizati ...... nt H5N1, H3N2 and H1N1 viruses
@en
Single-dose mucosal immunizati ...... nt H5N1, H3N2 and H1N1 viruses
@nl
P2093
P2860
P3181
P1433
P1476
Single-dose mucosal immunizati ...... nt H5N1, H3N2 and H1N1 viruses
@en
P2093
Chia-Yun Lo
Claudia Pappas
Graeme E Price
Julia A Misplon
Katherine V Houser
Mark R Soboleski
Mary R Quirion
Suzanne L Epstein
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0013162
P407
P577
2010-01-01T00:00:00Z